RhumbLine Advisers’s Annovis Bio ANVS Stock Holding History

RhumbLine Advisers’s Portfolio ANVS Stock Details ANVS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$780	Hold	350	–	–	﹤0.01%	3998
2025 Q4	$1.21K	Hold	350	–	–	﹤0.01%	4022
2025 Q3	$724	Hold	350	–	–	﹤0.01%	4041
2025 Q2	$759	Hold	350	–	–	﹤0.01%	4055
2025 Q1	$525	Hold	350	–	–	﹤0.01%	4054
2024 Q4	$1.76K	Hold	350	–	–	﹤0.01%	4044
2024 Q3	$2.82K	Buy	+350	New	+$3.28K	﹤0.01%	4040

Other funds holding ANVS

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

MFG

Merit Financial Group Alpharetta, Georgia $16.4B AUM 25.17% 1-Year Est. Return

RhumbLine Advisers's ANVS Position: Q1 2026 in Review

RhumbLine Advisers held its Annovis Bio (ANVS) position steady in Q1 2026 at 350 shares worth $780. The position accounts for ﹤0.01% of the portfolio, ranked #3998.

RhumbLine Advisers first reported a position in ANVS in Q3 2024 and has held it in 7 quarters since. The position peaked at $2.82K in Q3 2024. 56 funds tracked by Wall St. Rank hold ANVS as of Q1 2026.

RhumbLine Advisers held 350 shares of Annovis Bio worth $780 as of Q1 2026.
RhumbLine Advisers left its Annovis Bio share count unchanged in Q1 2026.
Annovis Bio made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #3998 holding.
RhumbLine Advisers first reported a position in Annovis Bio in Q3 2024 and has held it in 7 quarters since.
RhumbLine Advisers's Annovis Bio position peaked at $2.82K in Q3 2024.
56 funds tracked by Wall St. Rank held Annovis Bio as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.